Tao Wei; Wei-Hong Lv; Mei-Hua Gao; Shan-Juan Tan; Ling Li; Lei Zhang
Abstract
Background: The extent to which maternal antibodies against the hepatitis B surface antigen (HBsAb) acquired transplacentally affect the immune responses to the hepatitis B vaccine (HBVac) in infants is still uncertain.Objective: To explore the impact of the HBsAb on the immune response to the HBVac ...
Read More
Background: The extent to which maternal antibodies against the hepatitis B surface antigen (HBsAb) acquired transplacentally affect the immune responses to the hepatitis B vaccine (HBVac) in infants is still uncertain.Objective: To explore the impact of the HBsAb on the immune response to the HBVac in a mouse model.Methods: According to the doses of the HBVac (2, 5 μg) injected, 267 BALB/c mice were divided into two groups. Each group was subdivided into 3 subgroups based on the doses of the hepatitis B immunoglobulin (HBIG) (0, 25, 50 IU) administered. The HBsAb titers were detected 4 weeks after completing the HepB vaccination. Results: Among all the mice, 40 had an HBsAb titer <100 mIU/mL (non- or low-response to the HBVac). The rates of the HBsAb titer <100 mIU/mL in 0, 25 and 50 IU HBIG groups were 1.1%, 23.1%, and 20.7%, respectively. Multivariate logistic regression analysis showed that the risk factors for low- or non-response to the HBVac were injection with the HBIG, low HBVac dose, and hypodermic injection. The mean HBsAb titers (log10) reduced gradually in the 0, 25 and 50 IU HBIG groups (P<0.001).Conclusion: The HBIG administration has negative impacts on the peak level of the HBsAb and the rate of an effective immune response. This implies that the maternal HBsAb acquired transplacentally might inhibit the immune responses to the HBVac in infants.
Zahra Meshkat; Amir Teimourpour; Samira Rashidian; Mohsen Arzanlou; Roghayeh Teimourpour
Volume 13, Issue 4 , December 2016, , Pages 289-295
Abstract
Background: Tuberculosis is a life threatening disease that is partially prevented by
BCG vaccine. Development of more effective vaccines is an urgent priority in TB
control. Ag85a and Tb10.4 are the members of culture filter protein (CFP) of M.
tuberculosis that have high immunogenicity. Objective: ...
Read More
Background: Tuberculosis is a life threatening disease that is partially prevented by
BCG vaccine. Development of more effective vaccines is an urgent priority in TB
control. Ag85a and Tb10.4 are the members of culture filter protein (CFP) of M.
tuberculosis that have high immunogenicity. Objective: To analyze the
immunogenicity of Ag85a-Tb10.4 DNA vaccine by enzyme-linked immunosorbent
assay (ELISA). Methods: In this study a previously described plasmid DNA vaccine
encoding Ag85a-Tb10.4 was used to examine its capability in the stimulation of
immune responses in an animal model. Female BALB/c mice were vaccinated with 100
μg of purified recombinant vector intramuscularly 3 times at two-week intervals and the
levels of five cytokines including IFN-γ, IL-12, IL-4, IL-10 and TGF-β were measured.
Results: The levels of IFN-γ and IL-12 for the mice following immunization with
Ag85A-Tb10.4 was significantly greater than that of the BCG and control group
(p<0.05). However there was no significant difference in the levels of IL-4, IL-10 and
TGF-β between groups. Conclusion: IFN-γ and IL-12 Th1 cytokines increased
significantly in mice vaccinated with Ag85a-TB10.4 DNA vaccine in comparison to the
control and BCG groups. Our results may serve as groundwork for further research into
the prevention and treatment of tuberculosis.
Ghader Khalili; Faramarz Dobakhti; Hamid Mahmoudzadeh Niknam; Vahid Khaze; Fatemeh Partovi
Volume 8, Issue 1 , March 2011, , Pages 45-51
Abstract
Background: Leishmaniasis is a complex disease which presents as visceral, cutaneous and mucocutaneous forms. The current treatment options for this infection are very limited and the immunological state of the host appears to play an important role in the efficacy of the treatment. Immunostimulation ...
Read More
Background: Leishmaniasis is a complex disease which presents as visceral, cutaneous and mucocutaneous forms. The current treatment options for this infection are very limited and the immunological state of the host appears to play an important role in the efficacy of the treatment. Immunostimulation through immune response activating agents such as Imiquimod is another rational approach for this purpose. Objective: We assessed the efficacy of immunotherapy with Imiquimod alone or combined with Glucantime for treatment of Leishmania major infection in BALB/c mice. Methods: Treatment efficacy was monitored by determination of thickness and parasite load of infected footpad of mice. Results: The footpad thickness revealed that treatment with Imiquimod plus Glucantime has the highest efficacy. The results were confirmed by parasite load of infected footpad. Our data shows that treatment of Leishmania major infection in BALB/c mice by the combined Imiquimod and Glucantime is more efficient than each drug alone. Conclusion: The combination of Imiquimod with chemotherapy may offer a way for more efficient treatment of leishmaniasis.
Arash Mahboubi; Mohammad Reza Fazeli; Rasoul Dinavand; Nasrin Samadi; Mohammad Sharifzadeh; Houshmand Ilka; Saeed Azadi; Hassan Kalkouei; Rasoul Hajikhanmirzaei; Mahboubeh Valadkhani
Volume 5, Issue 3 , September 2008, , Pages 163-170
Abstract
Background: Several adjuvants have been evaluated for vaccine formulations but alu-minum salts will continue to be used for many years due to their safety, low cost and adjuvanticity with different antigens. Two commonly used aluminum adjuvants, alumi-num hydroxide and aluminum phosphate have different ...
Read More
Background: Several adjuvants have been evaluated for vaccine formulations but alu-minum salts will continue to be used for many years due to their safety, low cost and adjuvanticity with different antigens. Two commonly used aluminum adjuvants, alumi-num hydroxide and aluminum phosphate have different adjuvanticity properties. Com-mercial recombinant protein hepatitis B vaccines containing aluminum hydroxide is fac-ing low induction of immunity in some sections of the vaccinated population. Objec-tive: In this study, to follow the current global efforts in finding more potent hepatitis B vaccine formulations, adjuvanticity of aluminum phosphate, aluminum hydroxide and their combinations has been evaluated. Methods: The formulated vaccines were admin-istered intra-peritoneally (i.p.) to BALB/c mice and the titer of antibody was determined after 28 days using ELISA technique. The geometric mean of antibody titer (GMT, mIU/ml), seroconversion and seroprotection rates, ED50 (ng) and relative potency (μg/dose) of different formulations were determined. Results: GMT of antibody titer, seroconversion and seroprotection rates showed significantly higher adjuvanticity for aluminum phosphate than other formulations. The ED50 of aluminum phosphate was approximately two fold less than other formulations. Conclusion: Aluminum phosphate showed more adjuvanticity than aluminum hydroxide and their combinations in hepati-tis B protein vaccine. The use of aluminum phosphate as adjuvant leads to higher im-munity which may result in more protective response in vaccinated groups.
